论文部分内容阅读
目的评估加用比索洛尔对西宁地区肺源性心脏病 (肺心病 )心力衰竭的疗效。方法肺心病心力衰竭患者 63例 ,随机分为两组 ,常规治疗组 33例和比索洛尔组 30例。常规治疗组予以抗感染 ,吸氧 ,解痉止喘 ,止咳化痰 ,纠正水电解质及酸碱平衡等治疗 ;比索洛尔组在常规治疗的基础上 ,加比索洛尔 1 .2 5～ 2 .5mg/d ,口服 1月为一疗程。结果治疗 1月后 ,比索洛尔组总有效率为 88.2 4 % ,常规治疗组为 68.75 % ,两组比较有显著性差异 (P <0 .0 1 )。结论加用比索洛尔治疗肺心病心力衰竭其疗效优于常规治疗组 ,且未发现明显的副作用。
Objective To evaluate the effect of bisoprolol on heart failure in patients with pulmonary heart disease (pulmonary heart disease) in Xining. Methods 63 cases of heart failure patients with cor pulmonale were randomly divided into two groups: 33 cases in the conventional treatment group and 30 cases in the bisoprolol group. The conventional treatment group was given anti-infection, oxygen, antispasmodic and anti-asthma, cough and phlegm, water and electrolyte and acid-base balance to correct the treatment; bisoprolol group on the basis of conventional treatment, plus bisoprolol 1 .2 5 ~ 2 .5mg / d, oral January for a course of treatment. Results After 1 month of treatment, the total effective rate was 88.2% in the bisoprolol group and 68.75% in the conventional treatment group, with significant difference between the two groups (P <0.01). Conclusion The treatment with bisoprolol in patients with cor pulmonale heart failure is superior to the conventional treatment group, and no obvious side effects were found.